Cannon Advisors Inc. Purchases Shares of 3,971 Thermo Fisher Scientific Inc. $TMO

Cannon Advisors Inc. bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, HoldingsChannel.com reports. The fund bought 3,971 shares of the medical research company’s stock, valued at approximately $2,121,000. Thermo Fisher Scientific comprises 1.3% of Cannon Advisors Inc.’s investment portfolio, making the stock its 17th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Canada Post Corp Registered Pension Plan raised its position in Thermo Fisher Scientific by 11.7% in the second quarter. Canada Post Corp Registered Pension Plan now owns 45,314 shares of the medical research company’s stock valued at $22,719,000 after purchasing an additional 4,734 shares during the period. Independent Financial Group LLC increased its stake in Thermo Fisher Scientific by 29.0% during the 2nd quarter. Independent Financial Group LLC now owns 5,571 shares of the medical research company’s stock worth $2,793,000 after buying an additional 1,252 shares during the period. Security National Bank boosted its position in Thermo Fisher Scientific by 18.5% in the 2nd quarter. Security National Bank now owns 14,095 shares of the medical research company’s stock valued at $7,067,000 after buying an additional 2,205 shares during the last quarter. Matrix Asset Advisors Inc. NY grew its stake in shares of Thermo Fisher Scientific by 22.7% during the second quarter. Matrix Asset Advisors Inc. NY now owns 27,668 shares of the medical research company’s stock valued at $13,872,000 after acquiring an additional 5,121 shares in the last quarter. Finally, WealthBridge Investment Counsel Inc. increased its position in shares of Thermo Fisher Scientific by 2.2% during the second quarter. WealthBridge Investment Counsel Inc. now owns 12,852 shares of the medical research company’s stock worth $6,443,000 after acquiring an additional 275 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. This represents a 28.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 1.3%

TMO stock opened at $588.17 on Friday. The firm’s 50-day moving average is $529.37 and its two-hundred day moving average is $509.58. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $217.48 billion, a price-to-earnings ratio of 31.64, a price-to-earnings-growth ratio of 2.42 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. During the same period in the previous year, the firm earned $4.28 EPS. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on TMO shares. Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Piper Sandler upped their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research report on Monday, July 27th. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Morgan Stanley upped their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Royal Bank Of Canada boosted their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.